stockrowBristol Myers Squibb Company (BMY) vs Grifols, S.A. (GRFS)
- Bristol Myers Squibb Company BMY 62.14 −1.57%
- Grifols, S.A. GRFS 8.43 −0.35%
Bristol Myers Squibb Company and Grifols, S.A. are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $129.0B against $2.2B — 59.2× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.7× against 18.2×. Grifols, S.A. grew revenue faster over the last twelve months: 10.9% against 4.16%. Bristol Myers Squibb Company has the higher net margin (18.5% vs 6.02%) and the higher return on invested capital (13.2% vs 4.76%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.06% vs 1.12%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 13 and Grifols, S.A. on 10.
Valuation
Profitability
| Metric | BMY | GRFS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 37.55% | 73.01% |
| Operating margin | 22.65% | 16.69% | 18.34% |
| Net margin | 18.47% | 6.02% | 7.31% |
| Free cash flow margin | 18.56% | 8.51% | 18.56% |
| Return on equity | 44.01% | 5.80% | 5.80% |
| Return on assets | 9.96% | 2.28% | 2.28% |
| Return on invested capital | 13.19% | 4.76% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack